GSK Vaccines, Rockville Center for Vaccines Research, 14200 Shady Grove Road, Rockville, MD 20850, USA.
GSK Vaccines, Avenue Fleming 20, Parc de la Noire Epine, Wavre 1300, Belgium.
J Infect. 2022 Nov;85(5):481-491. doi: 10.1016/j.jinf.2022.09.001. Epub 2022 Sep 7.
Invasive meningococcal disease (IMD) is a life-threatening disease that can rapidly progress to death or leave survivors with severe, life-long sequelae. Five meningococcal serogroups (A, B, C, W and Y) account for nearly all IMD. Meningococcal serogroup distribution fluctuates over time across the world and age groups. Here, we consider the potential public health impact of a pentavalent MenABCWY vaccine developed to help further control meningococcal disease and improve immunisation rates.
The GSK MenABCWY vaccine combines the antigenic components of MenACWY-CRM (Menveo®) and 4CMenB (Bexsero®), building on a wide body of clinical experience and real-world evidence. Both approved vaccines have acceptable safety profiles, demonstrate immunogenicity, and are broadly used, including in national immunisation programmes in several countries. Since the advent of quadrivalent vaccines, public health in relation to IMD has improved, with a decline in the overall incidence of IMD and an increase in vaccine coverage.
A pentavalent MenABCWY has the potential to provide further public health benefits through practical, broad IMD protection programmes encompassing serogroups A, B, C, W and Y, and is currently in late-stage development.
侵袭性脑膜炎球菌病（IMD）是一种危及生命的疾病，可迅速发展为死亡，或使幸存者留下严重的、终身的后遗症。有五个脑膜炎奈瑟菌血清群（A、B、C、W 和 Y）几乎可导致所有 IMD。脑膜炎奈瑟菌血清群的分布在全球范围内随时间推移和年龄组而波动。在这里，我们考虑了一种五价 MenABCWY 疫苗的潜在公共卫生影响，该疫苗旨在帮助进一步控制脑膜炎球菌病并提高免疫接种率。
GSK 公司的 MenABCWY 疫苗结合了 MenACWY-CRM（Menveo®）和 4CMenB（Bexsero®）的抗原成分，这建立在广泛的临床经验和真实世界证据基础上。这两种已批准的疫苗都具有可接受的安全性、免疫原性，且使用广泛，包括在几个国家的国家免疫计划中。自从使用了四价疫苗以来，与 IMD 相关的公共卫生状况得到了改善，IMD 的总发病率下降，疫苗覆盖率增加。
五价 MenABCWY 疫苗具有通过实用、广泛的 IMD 保护计划提供进一步公共卫生效益的潜力，涵盖血清群 A、B、C、W 和 Y，目前处于后期开发阶段。
